As of November 12 at 9:20:20 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 6 | 7 |
| Avg. Estimate | 1.6B | 1.62B | 6.41B | 6.5B |
| Low Estimate | 1.56B | 1.57B | 6.37B | 6.25B |
| High Estimate | 1.64B | 1.65B | 6.52B | 6.84B |
| Year Ago Sales | 1.6B | 1.62B | 6.26B | 6.41B |
| Sales Growth (year/est) | -0.15% | -0.14% | 2.38% | 1.31% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 4OGN.TI | -- | -- | -- | -- |
| S&P 500 | 8.70% | 11.55% | 14.03% | 13.42% |
Upgrades & Downgrades
| Downgrade | JP Morgan: Neutral to Underweight | 9/6/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 5/6/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 5/3/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 4/29/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/20/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/22/2023 |